GeneDx Holdings Corp.

Listed Company

WGSCIK 0001818331NasdaqLarge AcceleratedServices-Health ServicesDelawareFY ends Dec 31

Period

FY 2025

Revenue

$427.54M

Net Income

$-21.02M

Total Assets

$523.71M

Equity

$308.18M

Shares Out

29.69M

Op. Cash Flow

$33.28M

WGSWW$0.00−96.59% · past yearDBEQ Basic

Daily closing prices

Business

GeneDx Holdings Corp. is a genomics-based clinical diagnostics company offering exome and genome sequencing tests (ExomeDx™ and GenomeDx™) for diagnosis of rare genetic diseases and disorders. The company provides comprehensive genetic testing powered by its proprietary GeneDx Infinity™ dataset—one of the world's largest rare disease databases from over 2.5 million tests—and combines this with clinical expertise, bioinformatics, and AI-driven variant interpretation to deliver fast, accurate diagnoses. GeneDx serves pediatric geneticists, pediatric specialists, general pediatricians, and healthcare systems in the United States, with expansion into neonatal intensive care, prenatal testing, newborn screening, and international markets via its Fabric Genomics acquisition.

Summary from 10-K filed 2026-02-23

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total revenue	428	305	203	235	212
Cost of services	129	111	113	261	229
Gross profit	298	194	90	−27	−17
Research and development	72	46	58	86	105
Selling and marketing	88	67	61	122	113
General and administrative	151	105	139	216	206
Impairment loss	0	0	10	210	0
Other operating expenses, net	0	0	2	6	—
Loss from operations	−13	−23	−181	−668	−446
Change in fair value of financial liabilities	−1	−13	1	—	—
Interest (expense) income, net	−3	−3	1	—	—
Other (expense) income, net	−4	−13	2	57,000	5
Total non-operating (expense) income, net	−8	−29	4	70	201
Loss before income taxes	−21	−53	−177	−598	−245
Income tax benefit	100,000	300,000	900,000	49	0
Net loss	−21	−52	−176	−549	−245
Unrealized gain related to available for sale securities, net	106,000	405,000	425,000	0	—
Comprehensive loss	−21	−52	−175	−549	−245
Basic weighted average shares outstanding of Class A common stock (in shares)	29	27	24	10	108
Diluted weighted average shares outstanding of Class A common stock (in shares)	29	27	24	10	108
Basic net loss per share, Class A common stock (in dollars per share)	−0.73	−1.94	−7.23	−53.63	−2.27
Diluted net loss per share, Class A common stock (in dollars per share)	−0.73	−1.94	−7.23	−53.63	−2.27

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	105	85	100	124	401
Marketable securities	66	56	30	0	—
Accounts receivable	74	38	—	43	27
Inventory, net	14	11	9	14	33
Prepaid expenses and other current assets	9	9	11	32	—
Total current assets	268	198	182	213	484
Operating lease right-of-use assets	23	26	27	33	0
Property and equipment, net	46	33	32	52	63
Goodwill	14	0	—	—	—
Intangible assets, net	168	159	173	187	0
Other assets	4	4	4	7	7
Total assets	524	419	419	491	554
Accounts payable and accrued expenses	58	31	37	85	—
Short-term lease liabilities	4	3	4	6	0
Other current liabilities	47	20	—	50	33
Total current liabilities	109	55	59	144	101
Long-term debt, net of current portion	48	52	53	6	11
Long-term lease liabilities	56	61	63	60	0
Other liabilities	2	6	15	24	22
Deferred taxes	757,000	965,000	2	3	0
Total liabilities	216	174	191	237	166
Purchase commitments and contingencies (Note 11)	—	—	—	—	—
Preferred Stock, $0.0001 par value: 1,000,000 shares authorized, 0 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively	0	0	0	0	0
Class A common stock, $0.0001 par value: 1,000,000,000 shares authorized, 29,245,296 and 28,016,545 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively	3,000	2,000	2,000	1,000	24,000
Additional paid-in capital	1,681	1,597	1,528	1,378	964
Accumulated deficit	−1,373	−1,352	−1,300	−1,124	−575
Accumulated other comprehensive income	936,000	830,000	425,000	0	—
Total stockholders equity	308	245	228	254	388
Total liabilities and stockholders equity	524	419	419	491	554

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization expense	25	22	34	59	—
Stock-based compensation expense	32	9	−326,000	42	219
Change in fair value of financial liabilities	1	13	−1	−70	−198
Provision for excess and obsolete inventory	135,000	180,000	4	1	2
Legal reserves	6	0	0	—	—
Change in third party payor reserves	2	607,000	−10	—	—
Other	3	3	−3	3	—
Accounts receivable	−36	−5	11	6	6
Inventory	−3	−3	975,000	2	−11
Accounts payable and accrued expenses	12	−21	−49	34	26
Other assets and liabilities	12	4	−575,000	−8	—
Net cash provided by (used in) operating activities	33	−28	−180	−319	−190
Purchases of marketable securities	−56	−66	−48	0	—
Proceeds from sales of marketable securities	2	601,000	0	—	—
Proceeds from maturities of marketable securities	44	41	18	—	—
Purchases of property and equipment	−19	−5	−5	−7	−9
Proceeds from sales of assets	0	0	4	0	—
Development of internal-use software assets	0	0	−461,000	−7	−11
Net cash used in investing activities	−62	−30	−44	−141	−21
Proceeds from offerings, net of issuance costs	47	46	143	0	—
Proceeds from issuance of stock pursuant to employee stock purchase plan	3	497,000	0	—	—
Exercise of stock options	2	394,000	285,000	3	1
Long-term debt principal payments	−1	−497,000	−2	0	−9
Finance lease payoff and principal payments	−3	−3	−4	−3	−4
Proceeds from long-term debt	0	0	49	0	0
Net cash provided by financing activities	48	44	186	197	494
Net increase (decrease) in cash, cash equivalents and restricted cash	20	−14	−38	−263	283
Cash paid for interest	6	7	3	2	3
Cash paid for taxes	1	1	1	1	349,000
Purchases of property and equipment in accounts payable and accrued expenses	6	3	134,000	0	761,000
Stock consideration paid pursuant to exercise of Perceptive warrant	0	13	0	—	—
Assets acquired under capital leases obligations	0	689,000	0	461,000	1
Issuance of common stock for first OPKO Milestone Payment	0	0	7	0	—
Lease liability from obtaining right-of-use asset	0	0	637,000	0	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is GeneDx Holdings Corp.'s CIK number?

GeneDx Holdings Corp.'s SEC CIK number is 0001818331 (1818331). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find GeneDx Holdings Corp.'s SEC filings?

All of GeneDx Holdings Corp.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did GeneDx Holdings Corp. last report earnings?

GeneDx Holdings Corp. (WGS) most recently filed an earnings 8-K with the SEC on May 4, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001818331-26-000039). This is GeneDx Holdings Corp.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is GeneDx Holdings Corp.'s most recent earnings 8-K?

GeneDx Holdings Corp.'s latest earnings 8-K (Item 2.02) was filed May 4, 2026 under accession 0001818331-26-000039. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View GeneDx Holdings Corp.'s latest earnings 8-K →
Look up any company's CIK number →